Abstract
Non-inferiority (NI) trials can be used in a situation when a new drug is expected to have a similar efficacy to its comparator but can offer other advantages over the existing drug, such as a more convenient method of administration or fewer side effects. Here, we discuss the advantages and disadvantages of NI trials from an ethical, methodological and regulatory perspective. We suggest that such trials should be designed to address simultaneously the objective of showing NI with regard to drug efficacy and the objective of establishing superiority of the additional advantages of a drug over its active comparator.
| Translated title of the contribution | Should non-inferiority drug trials be banned altogether? |
|---|---|
| Original language | Undefined/Unknown |
| Pages (from-to) | 601-604 |
| Number of pages | 4 |
| Journal | Drug Discovery Today |
| Volume | 18 |
| Issue number | 11-12 |
| Publication status | Published - 2013 |
Keywords
- Econometric and Statistical Methods: General
- Geneeskunde (GENK)
- Geneeskunde(GENK)
- Medical sciences
- Bescherming en bevordering van de menselijke gezondheid